DHT Holdings, Inc.: Letter to Shareholders from the Co-CEOs

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
48
DHT Holdings, Inc.: Letter to Shareholders from the Co-CEOs

February 10, 2017 

Dear Shareholder,

We are writing to update you on DHT's business and our current thinking.

As you know well from our communications to you, the tanker market is cyclical, seasonal and volatile, and we manage these cycles proactively through our approach to operations, costs and capital allocation. By following this strategy, we produced very strong operational results in 2016:   

  • The average earnings of our VLCC fleet came in at $43,300 per day for the year - a strong number in our opinion; 
  • We delivered stable and competitive operating cost for our ships reflecting our modern quality fleet of ships run by a very experienced team with a long-term view on safe and reliable operations;  
  • We have further driven down our administrative cost by right-sizing our organization following the Samco acquisition in 2014, benefits that will be evident in our financial results this year.
  • The above translated into a solid EBITDA of $209 million for 2016 equivalent to ~ $ 2.24 per outstanding share.

With asset values down some 25-30% last year and close to the trough levels we saw in 2013, we think we have reached a period of attractive asset prices whereby we will gradually focus on investment and fleet renewal.  In keeping with that outlook, we have just placed an order for two VLCC newbuildings at Hyundai in South Korea.  The shipyard has offered us early delivery in July and September 2018 in combination with attractive payment terms whereby we will pay 70% at delivery.  The contract price is very attractive and includes large deadweight design of 318,000 metric tons as well as our typical upgrades to the shipyard specification.  The ships will be financed by about 50% equity and 50% bank debt.  Importantly, the equity component will be funded with cash at hand and future cash flow, hence no additional shares will be issued to finance this project. The combination of the attractive contract price and prudent financing results in very competitive cash break-even levels of about $17,600 per day to cover operating expenses, dry docking, debt amortization and interest payments.      

We are allocating our capital to position DHT for growth in the long term and to return the most capital to you, the shareholder.  We have paid cash dividends in 28 consecutive quarters.  Our well defined capital allocation policy includes a formula based distribution related to earnings.  During periods with strong tanker earnings, the cash dividends have been generous yet prudent.  We have in fact paid a total of $1.27 per share as cash dividends over the past two years.  When earnings have run through softer periods, we have still paid quarterly cash dividends albeit in nominal numbers.  It is however important to see the dividends in relation to how our capital is allocated in general.  During the periods with strong cash flows, we also had the opportunity to prepay debt extraordinarily, and more recently, repurchase our convertible bond at a discount to par.  As mentioned earlier, we are now in a period where some of our cash flow will be applied towards what we think will be attractive investments for DHT while adhering to our stated capital allocation policy.                        

Other companies have recognized the value in our high quality asset base and our employees. Frontline, a Norwegian-based tanker company, made an unsolicited, non-binding and highly conditional offer to acquire DHT.  We understand why they want to buy DHT with our modern high quality fleet - we are also buyers of modern quality ships in this environment.  However, our board unanimously concluded that the offer of exchanging 1 share in DHT for 0.725 shares in Frontline (equivalent in value at the present time of about $5 per DHT share) was wholly inadequate and substantially undervalued our company and undervalued what DHT's contribution across key metrics would have been to a combined company.  Additionally and importantly, Frontline proposed to pay for us in highly inflated Frontline shares that trade significantly above their underlying ship values.  The result would have been a dilution of more than 20% of net asset value per share for DHT shareholders.  This is clearly unacceptable.  It should be recognized that our VLCC fleet has an average age of about 6 years whereas Frontline's VLCC fleet has an average age of almost 11 years.  Frontline's VLCCs represent about 40% of their total fleet based on broker values.  Their Suezmaxes and LR2 product tankers are relatively young but are predominantly built at what we consider to be second tier shipyards in China.

We like DHT's current position with a robust balance sheet, quality fleet, first class people, solid customer base and supportive banks.  We have a mix of fixed income contracts and spot exposure thereby protecting the downside yet retaining significant upside.  Our customers are some of the most demanding oil majors and refiners out there, which we think reflects well on our services and operations.  The fact that we extend contracts and get repeat business should be a testament to DHT as a trusted business partner. 

We are, as you know, meaningful shareholders ourselves and have a continuous focus on building and running a highly respected tanker company providing attractive returns to investors.  We believe the execution of our strategic plan will drive significant and sustainable value for our shareholders. 

With best regards,

Trygve P. Munthe                                                                    Svein Moxnes Harfjeld                   Co- CEO                                                                                       CO-CEO

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...4ff57dbe9c

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading